Medincell Stock Rises 3.11% to €27.20 at Midday

Oddo BHF Maintains 'Outperform' Rating, Raises Target

Investment bank Oddo BHF maintained its 'Outperform' recommendation on the stock on January 16, while raising its target from €27 to €34. This new level suggests a potential appreciation of nearly 25% from the current price. Analysts expect sales of Uzedy to be between €270 and €300 million in 2026, which could allow Medincell to earn between €12 and €13 million in royalties. The file for Olanzapine LAI was submitted to the US health authorities on December 9 after promising phase 3 results. Approval is hoped for by next October. Oddo BHF estimates that this treatment could become a blockbuster, generating one billion dollars per year. Additionally, the company has entered into an agreement with Abbvie, with the first drug candidate set to begin its clinical phase. Conversely, TP Icap Midcap has been more cautious, downgrading its recommendation to 'Hold' with a target set at €32.

RSI Normalizes, Stock Fluctuates Within Bollinger Bands

The RSI now stands at 58, indicating normalization after nearly reaching an overbought zone at 78 on January 26 during an 8.56% correction. The stock is currently fluctuating between a lower Bollinger band at €23.42 and an upper limit at €29.24. Breaking through the upper band could pave the way to the resistance threshold at €29.20, a level already tested recently. The price is slightly above its 50-day moving average of €27.04, suggesting a fragile bullish momentum that remains dependent on the evolution of fundamental data. The MACD histogram shows a positive value at 0.17, confirming the persistence of a constructive short-term dynamic despite fluctuations. The next key event for investors will be the publication of the annual results for the fiscal year 2025-2026 scheduled for June 16. This milestone will allow an assessment of Uzedy's commercial ramp-up and the progress of development programs.